A recent Geriatric Medicine digest,
as sent to subscribers

Study Type: Systematic review (narrative synthesis, no meta-analysis)

Key Question: Which neuropsychiatric symptom domains are most consistently associated with functional decline (ADL/IADL) in people with dementia?

Key Findings:

• 40 studies, 13,711 participants; NPS generally associated with poorer ADL/IADL performance.
• Apathy most consistently linked to decline longitudinally (6/9 studies); delusions (5/5) and hallucinations (3/3) showed fully consistent associations, with psychotic symptoms among the strongest predictors.
• Overall NPS burden also associated with worsening function, but consistency varied by domain and dementia subtype; evidence certainty was low to very low (GRADE).

Clinical Relevance: For UK geriatricians managing dementia in memory clinics and community settings, screening for apathy and psychotic symptoms may help flag patients at higher risk of accelerating functional dependency, informing care planning and social care referral timing.

Limitations: Heterogeneous study designs and low-to-very-low certainty longitudinal evidence limit causal inference and precluded meta-analysis.

Study Type: Retrospective cohort study (nationwide, population-based)

Key Question: How common are clinically significant prescribing cascades in older adults, and what factors predict their occurrence?

Key Findings:

• Among 16.6 million adults aged ≥65, 4 of 7 predefined prescribing cascades showed significant positive signals; incidence ranged from 0.69% to 3.29%.
• Strongest signals: benzodiazepine→antipsychotic (adjusted sequence ratio 2.48, 99% CI 2.44–2.51) and antipsychotic→antiparkinsonian (aSR 2.01, 99% CI 1.91–2.11).
• Female sex, age ≥85, hospital-initiated index drugs, and poor prescriber continuity increased cascade risk.

Clinical Relevance: Highlights a preventable, underrecognised driver of polypharmacy relevant to NHS medicines optimisation and STOPP/START-based reviews, particularly around care transitions and new psychotropic prescriptions.

Limitations: Reliance on administrative prescription data and sequence symmetry analysis limits causal inference and may misclassify true cascades versus coincidental prescribing.

Study Type: Retrospective cohort study (propensity-matched, US Nationwide Readmissions Database 2016–2022)

Key Question: Does endovascular thrombectomy (EVT) improve outcomes compared with best medical management (BMM) in acute LVO stroke patients with pre-existing dementia?

Key Findings:

• Overall, home discharge rates were similar between EVT and BMM (27.1% vs 26.4%, P=.51); EVT associated with longer length-of-stay and more intracranial haemorrhage (23.9% vs 11.1%, P<.001), with no mortality difference.
• Age significantly moderated benefit (interaction P<.001): EVT patients <75 years had higher home discharge (36.7% vs 26.8%, P<.001).
• Dementia subtype mattered: EVT benefit was greater in vascular dementia than Alzheimer's disease (32.7% vs 25.2%, P=.007; interaction P=.014).

Clinical Relevance: Supports a more nuanced, individualised approach to EVT decision-making in older UK stroke patients with dementia, suggesting selective benefit in younger-old patients and those with vascular dementia rather than blanket exclusion or inclusion based on dementia diagnosis alone.

Limitations: Retrospective administrative database design limits control for dementia severity, baseline functional status, and unmeasured confounding despite propensity matching.

Study Type: Narrative review

Key Question: What are the mechanisms underlying VEGFR inhibitor-induced cardiotoxicity and hepatotoxicity, and how might these inform prevention and monitoring strategies, particularly in older adults?

Key Findings:

• Clinical data show cardiovascular (arrhythmias, heart failure) and hepatic (enzyme elevation, hepatic failure) toxicities occurring in parallel rather than sequentially.
• Experimental studies implicate shared mechanisms: endothelial injury, oxidative stress, mitochondrial dysfunction, inflammation, dysregulated autophagy, apoptosis, and metabolic disturbance.
• No direct evidence supports cross-organ (cardio-hepatic) propagation; this remains a hypothetical framework rather than a proven mechanism.

Clinical Relevance: Older patients with reduced organ reserve, frailty, multimorbidity, and polypharmacy may be at heightened risk of VEGFR inhibitor toxicity, supporting the case for risk-adapted cardiac and hepatic surveillance in NHS oncology–geriatric shared-care pathways.

Limitations: As a narrative review, it synthesises largely preclinical mechanistic data alongside clinical observations without systematic methodology, limiting the strength of causal inference.

Study Type: Narrative review

Key Question: What is the current state and future direction of vaccine-based immunotherapy for neurodegenerative proteinopathies (Alzheimer's disease, Parkinson's disease, prion diseases)?

Key Findings:

• Vaccine strategies have evolved from first-generation, broad pan-protein immunogens to conformation-specific approaches targeting pathogenic protein conformers (e.g., misfolded amyloid-beta, alpha-synuclein, prion protein).
• Immunomodulation is critical to balancing therapeutic efficacy against autoimmune/inflammatory adverse effects (historically limiting earlier trials, e.g., AN1792 meningoencephalitis).
• Novel platforms and delivery systems, combined with biomarker-guided early intervention and multi-target adaptive immunisation, are proposed as key to future clinical success.

Clinical Relevance: Understanding the trajectory of vaccine immunotherapy is important for UK geriatricians as disease-modifying immunotherapies (following the precedent of amyloid-targeting monoclonal antibodies now under NHS evaluation) may soon extend to active vaccination strategies for dementia and parkinsonian syndromes.

Limitations: As a narrative review without systematic methodology or original trial data, conclusions are qualitative and subject to selection bias.

Study Type: Systematic review and mechanism-based evidence map

Key Question: How should specific in vitro cell-line models be matched to distinct Alzheimer's disease mechanisms to ensure appropriate experimental use and interpretation?

Key Findings:

• Synthesis of 93 studies shows AD-relevant cell lines are mechanism-specific, not interchangeable whole-disease models.
• SH-SY5Y suits Aβ-toxicity screening; N2a is optimal for APP processing/amyloidogenesis; HT-22 models oxidative glutamate toxicity/ferroptosis; PC12 is restricted to NGF-dependent neurite biology.
• Disease-level relevance requires orthogonal validation and higher-fidelity human models (organoids, blood-brain barrier systems).

Clinical Relevance: Clarifies the mechanistic scope and limitations of preclinical AD models underpinning drug discovery, helping clinicians critically appraise translational claims from laboratory-stage research relevant to future NHS dementia therapeutics.

Limitations: Single-database search (PubMed only) and reliance on classical, non-human cell lines limit generalisability to human disease biology.

Study Type: Commentary/viewpoint

Key Question: How should frailty be incorporated into eligibility and care pathways for anti-amyloid disease-modifying therapies in Alzheimer's disease?

Key Findings:

• Frailty may reduce anti-amyloid drug efficacy via chronic inflammation, impaired repair mechanisms, and multisystem dysregulation.
• Mixed brain pathologies are proposed to contribute to physical frailty progression, linking neurodegeneration and frailty biologically.
• No validated diagnostic-therapeutic pathway currently exists for frailty-stratified anti-amyloid treatment decisions.

Clinical Relevance: As NHS memory services prepare for potential adoption of anti-amyloid therapies, embedding frailty assessment alongside biomarker and imaging criteria could inform safer, more equitable patient selection and monitoring rather than blanket exclusion of frail older adults.

Limitations: This is an opinion piece without new empirical data, so proposed frailty-integrated pathways require prospective validation.

Study Type: Narrative review

Key Question: How do somatic mutations accumulate across the human lifespan, and what role might developmental windows (particularly puberty) play in shaping disease risk from somatic mosaicism?

Key Findings:

• Somatic mutations accumulate approximately linearly with age (from a few hundred per cell at birth to several thousand in old age), with rates varying several-fold by cell type and showing clock-like mutational signatures.
• Phylogenetic reconstructions place driver mutations in normal breast/prostate epithelium within the pubertal window, but existing datasets show only a small, non-significant excess mutation burden during puberty.
• Key mechanisms include DNA polymerase ε replication errors at CpG sites and cytosine deamination with error-prone repair; duplex/single-cell sequencing now enables detection of low-frequency variants.

Clinical Relevance: Understanding age- and stage-dependent somatic mutagenesis informs risk stratification for cancer and age-related disease, relevant to NHS cancer screening and healthy ageing strategies, though direct clinical application remains premature.

Limitations: Evidence for puberty as a vulnerability window is based on limited, underpowered datasets, and longitudinal human data across developmental stages are lacking.